Myomo (NASDAQ:MYO) Lowered to Neutral at Roth Capital

Roth Capital downgraded shares of Myomo (NASDAQ:MYO) from a buy rating to a neutral rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

Shares of Myomo stock traded down $0.03 on Wednesday, reaching $0.51. 58,200 shares of the company traded hands, compared to its average volume of 135,937. Myomo has a 52 week low of $0.43 and a 52 week high of $2.01. The company has a 50 day moving average of $0.63 and a 200 day moving average of $0.79.

Myomo (NASDAQ:MYO) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.16). The business had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $1.30 million.

About Myomo

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Featured Article: What is the Quick Ratio?

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.